A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor.

Nehal J. Lakhani,Drew W. Rasco,Anthony W. Tolcher,Yingjie Huang,Jiao Ji,Hengbang Wang,Qi Dong,Lichuang Men,Timothy J. O'Rourke,Sreenivasa R Chandana,Alex Amaya,Yvette Cole,Brianne Kaiser,Theresa Mays,Amita Patnaik,Kyriakos P. Papadopoulos,Dajun Yang,Yifan Zhai

A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor.

2018

Nehal J. Lakhani
Drew W. Rasco
Anthony W. Tolcher
Yingjie Huang
Jiao Ji
Hengbang Wang
Qi Dong
Lichuang Men
Timothy J. O'Rourke
Sreenivasa R Chandana
Alex Amaya
Yvette Cole
Brianne Kaiser
Theresa Mays
Amita Patnaik
Kyriakos P. Papadopoulos
Dajun Yang
Yifan Zhai

2594Background: We have developed a unique strategy to tactically reduce on-target platelet toxicity with APG-1252, a novel dual Bcl-2/Bcl-xL inhibitor, while maintaining strong in vivo antitumor a...

Keywords:

Cell
Lung cancer
Pathology
Cancer research
Bcl-xL
Medicine
bcl 2 bcl xl
solid tumor
in patient
Toxicity
In vivo
Platelet
non small cell
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations